000			02603na a2200325 4500
999			_c786 _d786
003			PC786
005			20191203062658.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aCiruelos Gil, Eva María _91082 _eOncología Médica
100			_aCortés-Funes Castro, Hernán _91181 _eOncología Médica
100			_aDorta Suárez, Myriam _92607 _eOncología Médica
100			_aGhanem Cañete, Ismael _91793 _eOncología Médica
100			_aManneh Kopp, Ray _92608 _eOncología Médica
100			_aManso Sánchez, Luis _9432 _eOncología Médica
100			_aMendiola Fernández, César _91804 _eOncología Médica
100			_aSepúlveda Sánchez, Juan Manuel _9433 _eOncología Médica
100			_aValdiviezo N, _92609 _eOncología Médica
100			_9301 _aVega Alonso, Estela _eOncología Médica
245	0	0	_aSafety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients. _h[artículo]
260			_bClinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, _c2013
300			_a15(6):467-71.
500			_aFormato Vancouver: Manso L, Valdiviezo N, Sepúlveda J, Ciruelos E, Mendiola C, Ghanem I, et al. Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients. Clin Transl Oncol. 2013 Jun;15(6):467-71.
501			_aPMID: 23263907
504			_aContiene 23 referencias
520			_aMetronomic administration of the same chemotherapy agents (lower doses with closer intervals) may optimize their antiangiogenic properties. The aim of our study was to determine the efficacy and safety of a metronomic regimen based in non-pegylated liposomal doxorubicin (NPLD) in advanced breast cancer patients.
710			_9303 _aServicio de Oncología Médica
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/7/pc786.pdf _ySolicitar documento
942			_n0 _2ddc _cART